44 completed. 44 Phase 2, 10 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 44 | Completed 44 |
| Phase 1 | 10 | Completed 10 |
| Phase 3 | 2 | Completed 2 |
Follow Staphylococcal Infections: new trials by email Literature Review of Staphylococcal Infections trials Research Report on Staphylococcal Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI) Sa-5Ag half dose non-adjuvanted, Sa-5Ag full dose non-adjuvanted, Sa-5Ag half dose adjuvanted - Infections, Soft Tissue | Phase 2 | Completed | GlaxoSmithKline | 226 | 2022-11-16 | 2025-05-08 |
| Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia AP-SA02, Placebo - Bacteremia, Staphylococcus Aureus | Phase 1 / Phase 2 | Completed | Armata Pharmaceuticals, Inc. | 56 | 2022-04-26 | 2026-03-23 |
| Nasal Photodisinfection in All Patients Presenting for Surgery for a Wide Range of Surgical Procedures methylene blue 0.01%/chlorhexidine gluconate 0.25% + light activation - Surgical Site Infections, Nosocomial Infection | Phase 2 | Completed | Ondine Biomedical Inc. | 322 | 2022-02-04 | 2022-08-22 |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia Cefazolin, Dalbavancin, Daptomycin - Staphylococcal Bacteraemia | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 200 | 2021-04-22 | 2024-12-10 |
| Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers TP-102 - Diabetic Foot Ulcer, Pseudomonas Aeruginosa Infection | Phase 1 / Phase 2 | Completed | Technophage, SA | 20 | 2021-03-22 | 2022-10-04 |
| Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection XF-73, Placebo - Staphylococcal Infections, Surgical Site Infection | Phase 2 | Completed | Destiny Pharma Plc | 124 | 2019-08-29 | 2023-10-16 |
| Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo ATx201, ATx201 GEL Vehicle - Impetigo | Phase 2 | Completed | UNION therapeutics | 210 | 2018-02-23 | 2018-07-31 |
| Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization NDV-3A, Placebo - Staphylococcus Aureus | Phase 2 | Completed | NovaDigm Therapeutics, Inc. | 382 | 2018-01-30 | 2020-01-29 |
| Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Hydroxychloroquine - Hidradenitis Suppurativa, Hidradenitis | Phase 1 / Phase 2 | Completed | Elena Gonzalez Brant, MD | 17 | 2017-09-28 | 2020-04-02 |
| Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia CF-301, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | Completed | ContraFect | 121 | 2017-05-23 | 2021-10-08 |
| Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Roseomonas mucosa - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 31 | 2017-04-20 | 2019-11-27 |
| Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU Mupirocin Topical Ointment, Petroleum Jelly - Staphylococcus | Phase 2 | Completed | Crouse Hospital | 216 | 2016-10-01 | 2020-12-21 |
| Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess Antimicrobial TheraGauze - Furunculosis | Phase 1 / Phase 2 | Completed | Eastern Virginia Medical School | 6 | 2016-04-01 | 2018-10-04 |
| SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults Staphylococcus aureus 4-antigen vaccine, Placebo - Staphylococcal Infections | Phase 2 | Completed | Pfizer | 136 | 2015-06-01 | 2018-07-30 |
| Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects. 514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment - Staphylococcus Aureus Bacteremia | Phase 1 / Phase 2 | Completed | XBiotech, Inc. | 52 | 2015-05-01 | 2026-02-09 |
| Study of the Efficacy and Safety of MEDI4893 MEDI4893, Placebo - Staphylococcus Aureus Pneumonia | Phase 2 | Completed | MedImmune LLC | 213 | 2014-10-10 | 2019-12-23 |
| Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects XF-73 nasal gel, Placebo nasal gel, Chlorhexidine gluconate 2% topical cloths - Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Completed | Destiny Pharma Plc | 60 | 2014-09-01 | 2016-10-07 |
| Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants Mupirocin calcium - Staphylococcal Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 155 | 2014-04-30 | 2017-07-07 |
| Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections Daptomycin, Brilacidin - Skin Infection, Bacterial Infection | Phase 2 | Completed | Cellceutix Corporation | 215 | 2014-02-01 | 2018-09-26 |
| Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation Vancomycin - Pneumonia, Staphylococcal, Methicillin-Resistant Staphylococcus Aureus | Phase 2 | Completed | Seoul National University Hospital | 20 | 2013-08-01 | 2019-04-23 |
Showing 20 of 44. Sign in to see all of them.
Impetigo (8) · Bacteremia (6) · Staphylococcal Skin Infections (5) · Abscess (4) · Cellulitis (4) · Sepsis (3) · Skin Diseases, Bacterial (3) · Dermatitis, Atopic (2) · Furunculosis (2) · Pneumonia, Staphylococcal (2) · Soft Tissue Infections (2) · Streptococcal Infections (2) · Surgical Wound Infection (2) · Acinetobacter Infections (1)
Bacterial Infections and Mycoses (44) · Gram-Positive Bacterial Infections (44) · Bacterial Infections (43) · Infections (43) · Skin and Connective Tissue Diseases (19) · Skin Diseases (17) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Skin Diseases, Infectious (16) · Skin Diseases, Bacterial (13) · Inflammation (12) · Staphylococcal Skin Infections (10) · Streptococcal Infections (9) · Systemic Inflammatory Response Syndrome (7)
Daptomycin (4) · Vancomycin (3) · Clindamycin (2) · Linezolid (2) · Mupirocin (2) · Trimethoprim, Sulfamethoxazole Drug Combination (2) · chlorhexidine gluconate (2) · 1-phenyl-3,3-dimethyltriazene (1) · Adjuvants, Pharmaceutic (1) · BID protein, human (1) · Cefazolin (1) · Cephalexin (1) · Fusidic Acid (1) · Hydroxychloroquine (1) · Inhalation (1)
National Institute of Allergy and Infectious Diseases (NIAID) (5) · Bristol-Myers Squibb (2) · Destiny Pharma Plc (2) · LEO Pharma (2) · Lytix Biopharma AS (2) · M.D. Anderson Cancer Center (2) · Melinta Therapeutics, Inc. (2) · Nabi Biopharmaceuticals (2) · NovaBay Pharmaceuticals, Inc. (2) · Aridis Pharmaceuticals, Inc. (1) · Armata Pharmaceuticals, Inc. (1) · Arrevus Inc. (1) · Cellceutix Corporation (1) · ContraFect (1) · Crouse Hospital (1)
United States (29) · Belgium (3) · France (3) · Israel (3) · South Africa (3) · Spain (3) · Australia (2) · Canada (2) · Czechia (2) · Dominican Republic (2) · Germany (2) · Greece (2) · Hungary (2) · Italy (2) · Russia (2)
Issam Raad, MD (2) · Seth Hetherington, M.D. (2) · Almena L Free, MD (1) · Daisy M Blanco, MD (1) · Daisy M. Blanco, MD (1) · Deborah Birx, MD (1) · Elena M Gonzalez Brant, MD (1) · Ian A Myles, M.D. (1) · Ian Mr Hayter, BSc (1) · Jae-Joon Yim, MD (1) · Jason W Bennett, MD (1) · Jeanne Breen, MD (1) · Jesus M Gonzalez Moreno, MD (1)
PMID 17893153, PMID 21537018, PMID 21546629, PMID 22837094, PMID 23099329, PMID 25448332, PMID 25785967, PMID 26482312, PMID 26962903, PMID 27025829, PMID 27795368, PMID 28535235, PMID 28657870, PMID 28987525, PMID 30343314, PMID 30587533, PMID 30926187, PMID 32050447, PMID 32271718, PMID 33894131, PMID 34023342, PMID 35578360, PMID 36951472, PMID 39740667, PMID 40802264, PMID 41800789, PMID 41999282
5UM1AI104681-12 (1)